1,3-二甲基-4-巯基-嘧啶-2-酮 | 49785-67-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 1,3-二甲基-4-巯基-嘧啶-2-酮
• 英文名称: 1,3-dimethyl-4-thiouracil
• 英文别名: 1,3-dimethyl-4-thioxo-1,2,3,4-tetrahydro-2-pyrimidinone；1,3-dimethyl-4-thioxo-3,4-dihydro-1H-pyrimidin-2-one；1,3-Dimethyl-4-thioxo-3,4-dihydro-1H-pyrimidin-2-on；3,4-dihydro-1,3-dimethyl-4-thioxo-2(1H)-pyrimidinone；1,2,3,4-Tetrahydro-1,3-dimethyl-2-oxo-4-thio-pyrimidin；1,3-Dimethyl-4-thio-uracil；1,3-dimethyl-4-sulfanylidenepyrimidin-2-one
• CAS: 49785-67-3
• 化学式: C₆H₈N₂OS
• mdl: MFCD00234221
• 分子量: 156.208
• InChiKey: PMKLUUOSOUESOS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  55.6
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1,3-二甲基-4-巯基-嘧啶-2-酮 在 二苯基硒亚砜 作用下， 以 乙醇 为溶剂， 生成 1,3-二甲基脲嘧啶
  参考文献：
  名称：

  Mikolajczyk, M.; Luczak, J., Journal of general chemistry of the USSR, 1988, vol. 58, # 9, p. 1804 - 1809

  摘要：

  DOI：
• 作为产物：
  描述：

  1,3-二甲基脲嘧啶 在 tetraphosphorus decasulfide 作用下， 生成 1,3-二甲基-4-巯基-嘧啶-2-酮
  参考文献：
  名称：

  尿嘧啶的直接th。

  摘要：

  DOI：

  10.1021/ja01201a025

文献信息

• Substituted-3,4-dihydro-4-(2,4,6-trime
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US04612376A1

  公开（公告）日：1986-09-16

  New pyrimidine derivatives of the formula: ##STR1## wherein Z is a group selected from ##STR2## in which R.sup.1 and R.sup.2 are each hydrogen, alkenyl, ar(lower)alkyl or lower alkyl optionally substituted with epoxy, hydroxy, amino and/or lower alkylamino and R.sup.5 is lower alkyl, R.sup.3 is hydrogen, aryl optionally substituted with lower alkyl, lower alkoxy and/or halogen, or pyridyl optionally substituted with lower alkyl, R.sup.4 is hydrogen, lower alkyl or phenyl optionally substituted with lower alkoxy, and Y is .dbd.O, .dbd.S or .dbd.N--R.sup.6, in which R.sup.6 is lower alkyl; cyclo(lower)alkyl; ar(lower)alkyl optionally substituted with lower alkoxy; N-containing unsaturated heterocyclic group optionally substituted with lower alkyl; or aryl optionally substituted with hydroxy, lower alkyl, halogen or lower alkoxy, in which lower alkoxy substituent may be substituted with epoxy, hydroxy, amino and/or lower alkylamino, provided that Y is .dbd.N--R.sup.6 when R.sup.3 and R.sup.4 are each hydrogen, and Y is .dbd.S or .dbd.N--R.sup.6 when R.sup.1 and R.sup.2 are each hydrogen or lower alkyl and R.sup.3 is phenyl, and pharmaceutically acceptable salts thereof, and processes for preparation thereof and pharmaceutical composition comprising the same. These derivatives and salts thereof are useful as cardiotonic, antihypertensive agent, cerebrovascular vasodilator and anti-platelet agent.

  新型嘧啶衍生物，其通式为：##STR1## 其中Z为选自##STR2##的基团，其中R1和R2各自为氢、烯基、芳基(低级)烷基或低级烷基，任选地被环氧、羟基、氨基和/或低级烷基氨基取代，R5为低级烷基，R3为氢、任选被低级烷基、低级烷氧基和/或卤素取代的芳基，或任选被低级烷基取代的吡啶基，R4为氢、低级烷基或任选被低级烷氧基取代的苯基，Y为＝O、＝S或＝N--R6，其中R6为低级烷基；环(低级)烷基；任选被低级烷氧基取代的芳基(低级)烷基；含氮的不饱和杂环基团，任选被低级烷基取代；或任选被羟基、低级烷基、卤素或低级烷氧基取代的芳基，其中低级烷氧基取代基可被环氧、羟基、氨基和/或低级烷基氨基取代，前提是当R3和R4各自为氢时，Y为＝N--R6，当R1和R2各自为氢或低级烷基且R3为苯基时，Y为＝S或＝N--R6，以及其药学上可接受的盐，以及其制备方法和包含它们的药物组合物。这些衍生物及其盐可作为强心剂、抗高血压药、脑血管扩张剂和抗血小板药使用。
• Synthesis of some new tetracyclic heteroaromatic chromans via quinone methide intermediates
  作者：Mohinder S. Chauhan、David M. McKinnon

  DOI：10.1139/v81-321

  日期：1981.7.15

  Synthesis of several new tetracyclic heteroaromatic chromans has been achieved through the reaction of various uracil and 1,3-thiazine derivatives with 1,2-naphthoquinone-1-methide. The spirodimer 4 is a better source of naphthoquinone methide than the naphthol derivatives which provide chromans in low yield due to side reactions. The structure and mechanisms of the various products formed are discussed

  通过各种尿嘧啶和 1,3-噻嗪衍生物与 1,2-萘醌-1-甲基化物的反应，合成了几种新的四环杂芳族色满。螺二聚体 4 是比萘酚衍生物更好的萘醌甲基化物来源，后者由于副反应而以低产率提供色满。讨论了形成的各种产品的结构和机制。
• Pyrimidine derivatives, preparation thereof and use thereof
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP0123402A2

  公开（公告）日：1984-10-31

  New pyrimidine derivatives of the formula: wherein Z is a group selected from in which R1 and R2 are each hydrogen, alkenyl, ar (lower) alkyl or lower alkyl optionally substituted with epoxy, hydroxy, amino and/or lower alkylamino and R5 is lower alkyl, R' is hydrogen, aryl optionally substituted with lower alkyl, lower alkoxy and/or halogen, or pyridyl optionally substituted with lower alkyl, R4 is hydrogen, lower alkyl or phenyl optionally substituted with lower alkoxy, and Y is =0, =S or =N-R6, in which R6 is lower alkyl; cyclo(lower)alkyl; ar(lower)alkyl optionally substituted with lower alkoxy; N-containing unsaturated heterocyclic group optionally substituted with lower alkyl; or aryl optionally substituted with hydroxy, lower alkyl, halogen or lower alkoxy, in which lower alkoxy substituent may be substituted with epoxy, hydroxy, amino and/or lower alkylamino, provided that Y is =N-R6 when R5 and R4 are each hydrogen, and Y is =S or =N-R6 when R' and R2 are each hyd- rogen or lower alkyl and R5 is phenyl, and pharmaceutically acceptable salts thereof, and processes for preparation thereof nad pharmaceutical composition comprising the same. These derivatives and salts thereof are useful as cardiotonic, antihypertensive agent, cerebrovascularvasodilator and anti-platelet agent.

  式中的新嘧啶衍生物： 其中 Z 是选自以下的基团 其中 R1 和 R2 分别为氢、烯基、ar（低级）烷基或被环氧、羟基、氨基和/或低级烷基氨基任选取代的低级烷基，R5 为低级烷基、 R' 是氢、任选被低级烷基、低级烷氧基和/或卤素取代的芳基或任选被低级烷基取代的吡啶基、 R4 是氢、低级烷基或任选被低级烷氧基取代的苯基，以及 Y 是 =0、=S 或 =N-R6、 其中 R6 是低级烷基；环（低级）烷基；任选被低级烷氧基取代的 ar（低级）烷基；任选被低级烷基取代的含 N 不饱和杂环基团；或任选被羟基、低级烷基、卤素或低级烷氧基取代的芳基，其中低级烷氧基取代基可被环氧、羟基、氨基和/或低级烷基氨基取代、 当 R5 和 R4 分别为氢时，Y 为＝N-R6；当 R' 和 R2 分别为氢或低级烷基且 R5 为苯基时，Y 为＝S 或＝N-R6。 这些衍生物及其盐类可用作强心剂、降压药、脑血管扩张剂和抗血小板药。
• Pyrimidines. 17. Novel pyrimidine to pyridine transformation reaction. One-step synthesis of pyrido[2,3-d]pyrimidines
  作者：Kosaku Hirota、Yukio Kitade、Shigeo Senda、Michael J. Halat、Kyoichi A. Watanabe、Jack J. Fox

  DOI：10.1021/jo00318a004

  日期：1981.2
• Cobalt-Mediated [2+2+2] Cycloadditions of Pyrimidine Derivatives to Alkynes
  作者：Hélène Pelissier、Jean Rodriguez、K. Peter C. Vollhardt

  DOI：10.1002/(sici)1521-3765(19991203)5:12<3549::aid-chem3549>3.0.co;2-v

  日期：1999.12.3

  The scope and limitations of the cobalt-mediated [2+2+2] cycloaddition of pyrimidine derivatives to alkynes has been investigated. The 5,6-double bond of these heterocyclic nuclei has been found to participate in an entirely intermolecular fashion to generate chemo- and stereoselectively novel, fused and substituted 5,6-dihydropyrimidine cobalt complexes, which upon oxidative demetallation liberate the corresponding new heterocyclic ligand. On the other hand, 1-alkynyl pyrimidines have been found to be suitable partners in the cocyclization with disubstituted alkynes, such as bis(trimethylsilyl)acetylene (BTMSA) or dimethyl 2-butyn-1,4-dioate (DMAD), to allow the direct preparation of hitherto unknown dihydropyrido[3,2-ij]quinazoline cobalt complexes. Effects of the substitution on the pyrimidine nucleus, the cocyclization partner, the complex auxiliary, and the reaction conditions were examined, and in some cases competing pathways that lead to [CpCo(cyclobutadienes) ], cyclopentadienone complexes, and compounds that arise from a C-H activation-type reaction were observed.